Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Pancoast tumour and superior vena cava obstruction

Respiratory · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

Stridor, inability to lie flat, rapidly worsening facial or tongue swelling, syncope, confusion, reduced consciousness or signs of cerebral oedema in suspected superior vena cava obstruction require immediate ABCDE assessment and same-day acute oncology, anaesthetic and interventional radiology involvement. New limb weakness, sphincter disturbance or severe spinal pain with an apical mass raises possible cord or root compression and needs emergency imaging and specialist escalation.

Synopsis

Recognise superior sulcus invasion and superior vena cava obstruction, distinguish their emergency features, and coordinate diagnosis, symptom relief and definitive cancer care safely.

  • A Pancoast tumour is a superior sulcus lung cancer whose importance comes from local invasion of the lower brachial plexus, sympathetic chain, ribs, vertebrae or subclavian vessels rather than a distinctive histological type.
  • Severe shoulder or scapular pain radiating down the medial arm, C8-T1 weakness or wasting, and ipsilateral Horner syndrome should prompt deliberate inspection of the lung apex even without cough or haemoptysis.
  • A normal or equivocal chest radiograph does not exclude an apical lesion; contrast-enhanced CT and targeted MRI answer different staging questions.
  • Superior vena cava obstruction causes facial, neck and upper-limb oedema, venous distension, plethora, dyspnoea and symptoms worsened by bending or lying flat.
  • The urgency of SVCO is determined by airway, cerebral and haemodynamic compromise, not by the dramatic appearance of chest-wall collaterals alone.
  • Obtain histology before tumour-directed treatment whenever the patient is stable, because small-cell cancer, non-small-cell cancer, lymphoma, germ-cell tumour and benign thrombosis require different therapy.
  • Contrast CT of the chest maps the obstruction, collateral circulation, thrombus and safest biopsy target; venography is usually reserved for planned endovascular treatment.
  • Endovascular stenting can relieve severe malignant SVCO rapidly, while chemotherapy or radiotherapy is selected by cancer type, stage, performance status and current commissioning guidance.
  • Do not prescribe corticosteroid or anticoagulation reflexively: steroid may compromise lymphoma diagnosis, and anticoagulation needs a thrombotic indication with bleeding risk assessed.
  • Every treatment decision belongs in an acute oncology or lung-cancer pathway, with local emergency protocols taking precedence over textbook summaries.

Key red flags

Neural or vertebral extension

Progressive arm weakness, severe radicular pain, long-tract signs, gait disturbance, urinary symptoms or a sensory level suggest foraminal or spinal canal extension and require urgent MRI and spinal or oncology advice.

Typical SVCO

Facial or neck swelling, bilateral arm swelling, dilated non-pulsatile neck or chest-wall veins, conjunctival suffusion, cough, dyspnoea, headache and a sensation of head fullness that worsens supine form the characteristic cluster.

High-grade SVCO

Stridor, laryngeal oedema, severe orthopnoea, confusion, syncope, reduced consciousness, visual disturbance or haemodynamic instability indicate threatened airway, cerebral congestion or impaired venous return and justify immediate specialist rescue planning.

Thrombotic phenotype

Abrupt symptoms, unilateral arm predominance, a tunnelled line, dialysis catheter, pacemaker lead or previous thrombosis increase the probability of an intraluminal component, although malignancy and thrombosis can coexist.

Investigation priorities

01
ABCDE assessment with neurological and airway examinationFirst step

Grade physiological threat before arranging definitive tests.

Management branches

SVCO emergencyStabilise threatened airway or brain

Stridor, rapidly progressive oedema, severe orthopnoea, confusion, syncope or reduced consciousness.

  1. Sit the patient upright, begin ABCDE monitoring, give oxygen for hypoxaemia and summon senior anaesthetic, acute oncology and interventional radiology help without delay.
  2. Use the fastest safe contrast imaging that will define obstruction and intervention, but do not force a severely orthopnoeic patient to lie flat without airway planning.
  3. Discuss urgent SVC stenting when rapid decompression is needed; arrange airway support and ensure any tension between biopsy and rescue treatment is resolved by the responsible specialists.
  4. After immediate danger is controlled, obtain or review tissue, evaluate thrombus and choose tumour-specific chemotherapy, radiotherapy or supportive care through the current MDT and local protocol.
Stable SVCOSecure diagnosis before definitive treatment

Venous obstruction without airway, cerebral or haemodynamic compromise.

  1. Grade symptoms, elevate the head, review existing imaging and contact acute oncology the same day rather than starting undirected treatment.

Key medicines

Controlled oxygenTitrate to 94-98% saturation for most adults, or 88-92% if at risk of hypercapnic respiratory failure pending blood gases.Oxygen does not relieve mechanical venous obstruction. Use a documented patient-specific target where present and repeat blood gases if hypercapnia is possible.
DexamethasoneUse only after senior acute-oncology advice at the dose in the current local oncological-emergency protocol.Not routine for every SVCO. It can impair lymphoma tissue diagnosis and causes hyperglycaemia, infection risk, delirium and gastrointestinal adverse effects; do not delay definitive decompression.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG122 lung cancer diagnosis and managementNational lung-cancer investigation, staging, treatment and SVCO recommendations.
  • NHS Scotland Right Decisions acute SVCO guidelineOperational grading and acute oncology escalation for SVCO.
  • NICE NG12 suspected cancer recognition and referralReferral framework for suspected lung and other cancers.
  • RCR radiotherapy dose fractionation fourth editionSpecialist radiotherapy reference; regimens remain oncology-led.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Obtain contrast CT and select the least hazardous biopsy route, preserving samples for lymphoma studies or lung-cancer biomarkers as the differential requires.
  • Assess whether symptoms, clot burden and predicted tumour responsiveness favour stenting, anticoagulation, systemic therapy, radiotherapy or a combination; record the decision and escalation plan.
  • Give clear return precautions for worsening breathlessness, voice change, swelling, headache, visual change, confusion or inability to lie flat.